Ocular manifestations of HIV infection

Current Opinion in Ophthalmology

Volumn 10, Issue 6, 1999, Pages 431-437

  Robinson, Michael R ^a   Ross, Michele L ^a   Whitcup, Scott M ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; DIDANOSINE; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; RIFABUTIN;

ARTICLE; CORNEA DISEASE; CYTOMEGALOVIRUS; EYE DISEASE; EYE TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROOPHTHALMOLOGY; PRIORITY JOURNAL; RETINITIS; UVEITIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CYTOMEGALOVIRUS RETINITIS; EYE DISEASES; HIV INFECTIONS; HUMANS; INCIDENCE;

EID: 0032698784     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199912000-00011     Document Type: Article

References (56)

1. 1 Freeman WR, Lerner CW, Mines JA, Lash RS, Nadel AJ, Starr MB, Tapper ML: A prospective study of the ophthalmologic findings in the acquired immunodeficiency syndrome. Am J Ophthalmol 1984, 97:133-142.
2. 2 Pepose JS: Ophthalmic manifestations of HIV infection. Curr Top AIDS 1989, 2:191-206.
3. 3 Kuppermann BD, Petty JG, Richman DD, Mathews WC, Fullerton SC, Rickman LS, Freeman WR: Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993, 115:575-582.
4. 4 Leahey AB, Shane JJ, Listhaus A, Trachtman M: Molluscum contagiosum eyelid lesions as the initial manifestation of acquired immunodeficiency syndrome. Am J Ophthalmol 1997, 124:240-241.
5. 5 Robinson MR, Udell IJ, Garber PF, Perry HD, Streeten BW: Molluscum contagiosum of the eyelids in patients with acquired immune deficiency syndrome. Ophthalmology 1992, 99:1745-1747.
6. 6 Hurni MA, Bohlen L, Furrer H, Braathen LR: Complete regression of giant molluscum contagiosum lesions in an HIV-infected patient following combined antiretroviral therapy with saquinavir, zidovudine and lamivudine [letter]. AIDS 1997, 11:1784-1785.
7. 7 Simonart T, Noel JC, De Clercq E, Snoeck R: Abatement of cutaneous Kaposi's sarcoma associated with cidofovir treatment [letter]. Clin Infect Dis 1998, 27:1562.
8. 8 Aboulafia DM: Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy. Mayo Clin Proc 1998, 73:439-443.
9. 9 Nanda M, Pflugfelder SC, Holland S: Fulminant pseudomonal keratitis and scleritis in human immunodeficiency virus-infected patients. Arch Ophthalmol 1991, 109:503-505.
10. 10 Silverstein BE: Parasitic corneal infections. Int Ophthalmol Clin 1998, 38: 179-182.
11. 11 Garvey MJ, Ambrose PG, Ulmer JL: Topical fumagillin in the treatment of microsporidial keratoconjunctivitis in AIDS. Ann Pharmacother 1995, 29: 872-874.
12. 12 Carr A, Marriott D, Field A, Vasak E, Cooper DA: Treatment of HIV-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998, 351:256-261.
13. 13 Geier SA, Libera S, Klauss V, Goebel FD: Sicca syndrome in patients infected with the human immunodeficiency virus. Ophthalmology 1995, 102:1319-1324.
14. 14 Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group: Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992, 326:213-220.
15. 15 Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, et al.: Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997, 126:257-263.
16. 16 Perry CM, Balfour JA: Fomivirsen. Drugs 1999, 57:375-381. Fomivirsen, the newest antiviral agent approved by the FDA for the treatment of CMVR, uses antisense technology to inhibit replication of CMV. It is administered by direct intravitreal injection at monthly intervals for maintenance therapy.
17. 17 Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, et al.: Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995, 333:615-620.
18. 18 Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S, et al.: Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996, 334:1491-1497.
19. 19 Jung D, Dorr A: Single-dose pharmacokinetics of valganciclovir in HIV-and CMV-seropositive subjects. J Clin Pharmacol 1999, 39:800-804.
20. 20 The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group: Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. Arch Ophthalmol 1996, 114:23-33.
21. 21 Lalezari JP, Kuppermann BD: Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:S27-S31.
22. 22 Cochereau-Massin I, Lehoang P, Lautier-Frau M, Zazoun L, Marcel P, Robinet M, et al.: Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1991, 98: 1348-1353.
23. 23 Kirsch LS, Arevalo JF, Chavez de la Pax E, Munguia D, de Clercq E, Freeman WR: Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1995, 102:533-543.
24. 24 Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann DB: Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 1997, 337:83-90.
25. 25 Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA: Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999, 340: 1063-1070. In HIV-infected patients with CMVR, the incidence of systemic CMV disease was significantly reduced by systemic ganciclovir combined with a ganciclovir implant compared with the implant alone.
26. 26 Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860. In a study of 1255 patients with HIV infection between 1994 and 1997, combination antiretroviral therapy including a protease inhibitor was associated with a threefold reduction in the mortality rate and a sixfold reduction in the rate of major opportunistic infections, including CMV retinitis.
27. 27 Centers for Disease Control and Prevention: HIV/AIDS surveillance report. 1997, 9:21.
28. 28 Jabs DA, Bartlett JG: AIDS and ophthalmology: a period of transition [editorial]. Am J Ophthalmol 1997, 124:227-233.
29. 29 Whitcup SM, Fortin E, Nussenblatt RB, Polis MA, Muccioli C, Belfort R Jr: Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis. JAMA 1997, 277:1519-1520.
30. 30 Whitcup SM, Cunningham ET Jr, Polis MA, Fortin E: Spontaneous and sustained resolution of CMV retinitis in patients receiving highly active antiretroviral therapy [letter]. Br J Ophthalmol 1998, 82:845-846.
31. 31 Reed JB, Schwab IR, Gordon J, Morse LS: Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS. Am J Ophthalmol 1997, 124:199-205.
32. + cell counts increase to more than 100 cells/μL with HAART.
33. + cell count of 100 cells/μL sustained for at least 4 months.
34. 34 Michelet C, Arvieux C, Francois C, Besnier JM, Rogez JP, Breux JP, et al.: Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998, 12:1815-1822.
35. 35 Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, et al.: Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1937, 349:1443-1445.
36. 36 Silverstein BE, Smith JH, Sykes SO, Jones MR, Schwartz D, Cunningham ET Jr: Cystoid macular edema associated with cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1998, 125:411-415.
37. 37 Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group: Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5, Clinical features of cytomegalovirus retinitis at diagnosis. Am J Ophthalmol 1997, 124:141-157.
38. 38 Palestine AG, Frishberg B: Macular edema in acquired immunodeficiency syndrome-related microvasculopathy [letter]. Am J Ophthalmol 1991, 111: 770-771.
39. 39 Zegans ME, Walton RC, Holland GN, O'Donnell JJ, Jacobson MA, Margolis TP: Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998, 125:292-300.
40. 40 Karavellas MP, Plummer DJ, Macdonald JC, Torriani FJ, Shufelt CL, Azen SP, Freeman WR: Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999, 179:697-700. Posterior-segment inflammation, including macular edema and vision loss, occurred in HIV-infected patients with inactive CMVR who were receiving HAART.
41. 41 Cassoux N, Lumbroso L, Bodaghi B, Zazoun L, Katlama C, LeHoang P: Cystoid macular oedema and cytomegalovirus retinitis in patients with HIV disease treated with highly active antiretroviral therapy. Br J Ophthalmol 1999, 83:47-49. Patients with HIV infection and inactive CMVR developed vitritis, macular edema, and vision loss after immune recovery resulting from HAART. Topical steroids and oral acetazolamide did not alleviate the macular edema, but periocular steroids were successful in some patients.
42. 42 Whitcup S, Robinson M, Csaky K: Visual morbidity with immune recovery uveitis in patients with cytomegalovirus retinitis [abstract]. Invest Ophthalmol Vis Sci 1999, 40:S189.
43. 43 Henderson H, Mitchell S: Treatment of immune recovery uveitis with local steroids. Br J Ophthalmol 1999, 83:540-545. Patients with immune recovery uveitis were treated with orbital-floor steroids with encouraging results.
44. 44 Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL, Japour AJ: Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998, 351: 252-255.
45. 45 Phillips P, Kwiatkowski MB, Copland M, Craib K, Montaner J: Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:122-128.
46. 46 Woods ML 2d, MacGinley R, Eisen DP, Allworth AM: HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 1998, 12:1491-1494.
47. 47 John M, French MA: Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust 1998, 169:473-474.
48. 48 Shafran SD, Deschenes J, Miller M, Phillips P, Toma E: Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin and ethambutol. N Engl J Med 1994, 330:438-439.
49. 49 Kuppermann BD: Therapeutic options for resistant cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:S13-S21.
50. 50 Akler ME, Johnson DW, Burman WJ, Johnson SC: Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis. Ophthalmology 1998, 105:651-657.
51. 51 Davis JL, Taskintuna I, Freeman WR, Weinberg DV, Feuer WJ, Leonard RE: Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997, 115:733-737.
52. 52 Ambati J, Robinson MR: Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. Br J Ophthalmol 1999, 83: 1153-1158.
53. 53 Nichols CW: Mycobacterium avium complex infection, rifabulin and uveitis-is there a connection? Clin Infect Dis 1996, 22:S43-S47.
54. 54 Smith JA, Mueller BU, Nussenblatt RB, Whitcup SM: Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia. Am J Ophthalmol 1999, 127:164-169. Patients with HIV infection who are receiving rifabutin prophylaxis for Mycobacterium avium complex disease may develop corneal endothelial deposits that are not inflammatory in origin and are not sight threatening.
55. 55 Kelleher P, Helbert M, Sweeney J, Anderson J, Parkin J, Pinching A: Uveitis associated with rifabutin and macrolide therapy for Mycobacterium avium intracellulare infection in AIDS patients, Genitourin Med 1996, 72:419-421.
56. 56 Whitcup S, Robinson M: Ocular manifestations of HIV in the pediatric population. In Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents, edn 3. Edited by Pizzo P, Wilfert C. Baltimore: Lippincott Williams & Wilkins; 1998:309-321. Didanosine has been associated with retinal toxicity in patients treated for HIV infection. Retinal pigment epithelial mottling in the peripheral retina with changes in the electrooculography are consistent with didanosine toxicity; dose reduction is recommended.